Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Urban, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Urban, T.
(Chest. 1998;114:1538-1541.)
© 1998 American College of Chest Physicians

Prognostic Significance of Supraclavicular Lymph Nodes in Small Cell Lung Cancer

A Study From Four Consecutive Clinical Trials, Including 1,370 Patients

Thierry Urban MD1; Claude Chastang MD, PhD2; Fabien Vaylet MD3; Marc Mathieu MD4; Pascal Leclerc MD5; Dominique Paillotin MD6; Bernard Lebeau MD1; and ;the "Petites Cellules" Group

1 From the Service de Pneumologie, Hôpital Saint-Antoine, Paris
2 From the Département de Biostatistique et Informatique Médicale, Hôpital Saint-Louis, Paris
3 From Services de Pneumologie, Hôpitaux de Percy-Clamart, Clamart, France
4 From Aulnay sous Bois, France
5 From Saint Germain en Laye, France
6 From Bois-Guillaume, France

Thierry Urban, MD, Service de Pneumologie, Hôpital Saint-Antoine, 184 rue du Faubourg Saint-Antoine, 75012 Paris, France; e-mail: thierry.urban{at}sat.ap-hop-paris.fr

Study objective: To determine the prognostic significance of supraclavicular lymph node (SCLN) involvement in small cell lung cancer.

Materials and methods: Patients (1,370) with small cell lung cancer were included in four consecutive clinical trials and classified as having either limited or extensive forms of disease using the Veterans Administration staging system.

Results: SCLN was present in 17% of patients (n = 234). Median survival was 258 days for patients with SCLN (n = 234) and 297 days for patients without SCLN (n = 1136) (p = 0.002). SCLN involvement was correlated with the presence of distant metastases at baseline (169 vs 65, p = < 0.001). Median survival was 375 days for patients with limited forms without SCLN (n = 529), 332 days for those with limited forms with SCLN (n = 65) (p = 0.12), 244 days for those with extensive forms without SCLN (n = 604), and 228 days for those with extensive forms with SCLN (n = 169) (p = 0.94). The 2-year survival rates were 17%, 12%, 2%, and 4%, respectively. Cox models confirmed that SCLN did not provide any significant additional prognostic information.

Conclusion: SCLN is highly correlated with extensive forms explaining its overall prognostic value. In limited disease, SCLN is only a minor poor prognostic factor, not justifying any amendment to the staging system currently used.

Key Words: lymph node • prognostic factors • small cell lung cancer • supraclavicular lymph node

Submitted on December 29, 1997
Accepted on June 12, 1998






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American College of Chest Physicians.